Johnson & Johnson drops two CAR-T lymphoma programs as market competition intensifies
read at Endpoints ↗Negative
Johnson & Johnson announced it is discontinuing two CAR-T cell therapy programs aimed at treating B-cell lymphoma.
The decision comes as the market for lymphoma treatments has become crowded, with several recent approvals of cell-based and antibody therapies.
By axing the programs, J&J will reallocate resources to other areas, highlighting the challenges of bringing new CAR-T products to market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “J&J axes pair of CAR-T therapies for lymphoma, citing evolving market”
read at Endpoints ↗83 words · retrieved May 1
comments(0)
5-min edit window · permanent after that